{"id":1414,"date":"2007-04-10T20:34:54","date_gmt":"2007-04-10T19:34:54","guid":{"rendered":"http:\/\/localhost\/covdev2\/index.php\/2007\/04\/10\/gsk-announce-meningitis-vaccine-for-africa\/"},"modified":"2007-06-08T15:41:21","modified_gmt":"2007-06-08T14:41:21","slug":"gsk-announce-meningitis-vaccine-for-africa","status":"publish","type":"post","link":"https:\/\/www.covalence.ch\/index.php\/2007\/04\/10\/gsk-announce-meningitis-vaccine-for-africa\/","title":{"rendered":"GSK announce meningitis vaccine for Africa"},"content":{"rendered":"<p><a href=\"http:\/\/www.ethicalquote.com\/newTemplate\/docs\/070410_GSKannouncemeningitisvaccineforAfrica.pdf\" target=\"_blank\"><img decoding=\"async\" src=\"http:\/\/www.ethicalquote.com\/newTemplate\/v2\/wp-content\/uploads\/2007\/04\/070410_gsk.gif\" title=\"070410_gsk.gif\" alt=\"070410_gsk.gif\" align=\"right\" \/><\/a><\/p>\n<p>British pharmaceutical giant GlaxoSmithKline (GSK) have announced the  development of a vaccine for use in African meningitis belt countries that the  company says will never make a profit or even recoup its R&amp;D costs. The vaccine  is Globorix\u00e2\u201e\u00a2, primarily a conjugate meningitis A &amp; C vaccine, which will also  protect children against other diseases such as diphtheria, tetanus and  hepatitis B. The demand for approval of Globorix\u00e2\u201e\u00a2 was made under article 58 of  the EMEA (European Medicines Agency) regulation 726\/2004 which allows a company  to ask the agency for a scientific opinion on the efficacy, quality and safety  of a medicinal product for use exclusively outside the EU in cooperation with  the WHO. This procedure is designed to help developing country medicines  agencies to approve much needed medicinal products. According to Jean St\u00e9phenne,  President of GlaxoSmithKline Biologicals, the development of Globorix\u00e2\u201e\u00a2 reflects  \u201cGSK\u2019s long-standing commitment to the developing world\u201d and meets \u201ca pressing  public health threat in Africa\u201d. Image source: whatistheworld.com<\/p>\n<p>Message received by Covalence <span class=\"LinkBlueTransMedium\">| Country: <\/span><span class=\"LinkBlueTransMedium\"><\/span><span class=\"LinkBlueTransMedium\">Global | Company: <\/span><span class=\"LinkBlueTransMedium\"><\/span><a href=\"http:\/\/www.ethicalquote.com\/newTemplate\/index.php\/ethicalquote\/?value=8\" class=\"LinkBluePgtMedium\">GlaxoSmithKline<\/a> <span class=\"LinkBlueTransMedium\"><span class=\"LinkBluePgtMedium\"><\/span><\/span><span class=\"LinkBlueTransMedium\"><\/span><span class=\"LinkBlueTransMedium\">| <\/span>Source: <a href=\"http:\/\/www.ethicalquote.com\/newTemplate\/docs\/070410_GSKannouncemeningitisvaccineforAfrica.pdf\" target=\"_blank\" class=\"LinkBluePgtMedium\">Rebecca Taylor, Fleishman-Hillard\u2019s EU<\/a><a href=\"http:\/\/www.ethicalquote.com\/newTemplate\/docs\/070410_GSKannouncemeningitisvaccineforAfrica.pdf\" target=\"_blank\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>British pharmaceutical giant GlaxoSmithKline (GSK) have announced the development of a vaccine for use in African meningitis belt countries that the company says will never make a profit or even recoup its R&amp;D costs. The vaccine is Globorix\u00e2\u201e\u00a2, primarily a conjugate meningitis A &amp; C vaccine, which will also protect children against other diseases such&hellip;<\/p>\n","protected":false},"author":665,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"wds_primary_category":0,"wds_primary_post_series":0,"footnotes":""},"categories":[6],"tags":[62],"post_series":[],"class_list":["post-1414","post","type-post","status-publish","format-standard","hentry","category-messages","tag-gsk","entry","no-media"],"_links":{"self":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1414","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/users\/665"}],"replies":[{"embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/comments?post=1414"}],"version-history":[{"count":0,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/posts\/1414\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/media?parent=1414"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/categories?post=1414"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/tags?post=1414"},{"taxonomy":"post_series","embeddable":true,"href":"https:\/\/www.covalence.ch\/index.php\/wp-json\/wp\/v2\/post_series?post=1414"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}